Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
New therapeutic target discovered for idiopathic pulmonary fibrosis

New therapeutic target discovered for idiopathic pulmonary fibrosis

Mutations in PARN and RTEL1 associated with familial pulmonary fibrosis, telomere shortening

Mutations in PARN and RTEL1 associated with familial pulmonary fibrosis, telomere shortening

Veracyte launches new genomic test to improve lung cancer diagnosis

Veracyte launches new genomic test to improve lung cancer diagnosis

Veracyte, GE parnter to develop new solutions to improve disease diagnosis

Veracyte, GE parnter to develop new solutions to improve disease diagnosis

New study describes way to regenerate lung tissue after injury

New study describes way to regenerate lung tissue after injury

Cambridge scientists successfully create 'mini-lungs' to study cystic fibrosis

Cambridge scientists successfully create 'mini-lungs' to study cystic fibrosis

Researchers identify promising new approach to treat pulmonary fibrosis

Researchers identify promising new approach to treat pulmonary fibrosis

Study explores outcomes of lung transplantations after implementing need-based allocation system

Study explores outcomes of lung transplantations after implementing need-based allocation system

Prime Therapeutics recognized with PBMI's 2015 Rx Innovation Award

Prime Therapeutics recognized with PBMI's 2015 Rx Innovation Award

UM SOM launches ‘Program in Lung Healing’ to develop treatments for acute respiratory failure

UM SOM launches ‘Program in Lung Healing’ to develop treatments for acute respiratory failure

TERT mutations may make smokers more susceptible to emphysema

TERT mutations may make smokers more susceptible to emphysema

Biogen Idec, Columbia University Medical Center form $30 million genomics research alliance

Biogen Idec, Columbia University Medical Center form $30 million genomics research alliance

2014 Canadian Prix Galien for Innovative Product Award presented to Esbriet (pirfenidone)

2014 Canadian Prix Galien for Innovative Product Award presented to Esbriet (pirfenidone)

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Yale University researchers study potential new treatment to reverse effects of pulmonary fibrosis

Yale University researchers study potential new treatment to reverse effects of pulmonary fibrosis

Researchers suggest that proportion of IPF may be due to unknown exposure to asbestos

Researchers suggest that proportion of IPF may be due to unknown exposure to asbestos

New data from Boehringer's Phase III trial program evaluates efficacy of tiotropium in asthma patients

New data from Boehringer's Phase III trial program evaluates efficacy of tiotropium in asthma patients

Viewpoints: Medicare no longer 'busting' the budget; a 'nightmare' trying to get coverage in D.C.

Viewpoints: Medicare no longer 'busting' the budget; a 'nightmare' trying to get coverage in D.C.

Chronic obstructive pulmonary disease flare-ups: an interview with Dr. MeiLan Han, University of Michigan and Scott Cerreta, Director of Education, COPD Foundation

Chronic obstructive pulmonary disease flare-ups: an interview with Dr. MeiLan Han, University of Michigan and Scott Cerreta, Director of Education, COPD Foundation

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.